BzATP triethylammonium

CAS: 112898-15-4 F: C30H39N6O15P3 W: 816.58

BzATP triethylammonium acts as a P2X receptor agonist with pEC50s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1,

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	BzATP triethylammonium acts as a P2X receptor agonist with pEC50s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively[1]. BzATP triethylammonium is potent at P2X7 receptors with EC50s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively[2].
Target	pEC50: 8.74 (P2X1), 5.26 (P2X2), 7.10 (P2X3), 6.19 (P2X2/3), 6.31 (P2X4), 5.33 (P2X7)EC50 3.6 μM (rat P2X7); 285 μM (mouse P2X7)
Invitro	BzATP (10-1000 μM；24 小时) triethylammonium 促进 U87 和 U251 胶质瘤细胞的增殖和迁移[3]。BzATP (100 μM；6-48 小时) triethylammonium 在人类胶质瘤细胞中诱导 P2X7R 蛋白表达。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> BzATP triethylammonium 相关抗体: Cell Proliferation Assay[3] Cell Line:
In Vivo	与假手术组和对照组相比，在盲肠结扎穿刺 (CLP) 诱导后，BzATP (5 mg/kg) triethylammonium 显著促进肠道中 P2X7R 的表达[4]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
CAS	112898-15-4
Formula	C30H39N6O15P3
Molar Mass	816.58
Appearance	固体
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Reference	[1]. B R Bianchi, et al. Pharmacological characterization of recombinant human and rat P2X receptor subtypes. Eur J Pharmacol. 1999 Jul 2;376(1-2):127-38. [2]. Mark T Young, et al. Amino acid residues in the P2X7 receptor that mediate differential sensitivity to ATP and BzATP. Mol Pharmacol. 2007 Jan;71(1):92-100. [3]. Zhenhua Ji, et al. Involvement of P2X 7 Receptor in Proliferation and Migration of Human Glioma Cells. Biomed Res Int. 2018 Jan 9;2018:8591397. [4]. Xiuwen Wu, et al. Systemic blockade of P2X7 receptor protects against sepsis-induced intestinal barrier disruption. Sci Rep. 2017 Jun 29;7(1):4364.